Satellos Bioscience Inc. (MSCL.TO)
CAD 0.64
(1.59%)
CAD 0.64
(1.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -22.06 Million CAD | -1046.93% |
| 2022 | -1.92 Million CAD | 60.5% |
| 2021 | -4.87 Million CAD | -1396.3% |
| 2020 | 375.78 Thousand CAD | 194.15% |
| 2019 | -399.12 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -9.83 Million CAD | 25.04% |
| 2024 Q1 | -13.11 Million CAD | 40.57% |
| 2023 FY | -22.06 Million CAD | -1046.93% |
| 2023 Q2 | -46.65 Million CAD | -4773.37% |
| 2023 Q1 | -957.26 Thousand CAD | 50.25% |
| 2023 Q3 | -44.26 Million CAD | 5.12% |
| 2023 Q4 | -22.06 Million CAD | 50.15% |
| 2022 Q3 | -3.13 Million CAD | 0.0% |
| 2022 Q4 | -1.92 Million CAD | 38.54% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 372.757% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | -88.253% |
| Helix BioPharma Corp. | -1.08 Million CAD | -1941.351% |
| Microbix Biosystems Inc. | -4.96 Million CAD | -344.795% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | -29.943% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 29.07% |
| Sernova Corp. | -8.58 Million CAD | -157.02% |